SUPPLY AND SERVICES AGREEMENTSupply and Services Agreement • September 27th, 2012 • Lorus Therapeutics Inc • Biological products, (no disgnostic substances) • Ontario
WHEREAS pursuant to the terms of an asset purchase agreement made as of the date hereof and certain related transactions, EMBI acquired sole and absolute ownership in certain intellectual property relating to the extraction of a product from bovine bile and known by the trade name “Virulizin”;
SETTLEMENT AGREEMENTSettlement Agreement • September 27th, 2012 • Lorus Therapeutics Inc • Biological products, (no disgnostic substances) • Ontario
WHEREAS on October 6, 2004, Lorus Therapeutics Inc. (formerly 4325231 Canada Inc.) (“Old Lorus”), GeneSense Technologies Inc. (“GeneSense”) and TEMIC entered into a subscription agreement (as amended, restated, supplemented or otherwise modified from time to time, the “Subscription Agreement”) providing for the issuance of three (3) five million dollar ($5,000,000) principal amount convertible debentures (each a “Debenture” and collectively, the “Debentures”) on each of October 6, 2004, January 14, 2005 and April 15, 2005, each maturing on October 6, 2009;
ANIMAL RIGHTS LICENSE AGREEMENTAnimal Rights License Agreement • September 27th, 2012 • Lorus Therapeutics Inc • Biological products, (no disgnostic substances) • Ontario
WHEREAS Lorus and The Erin Mills Investment Corporation (“TEMIC”) have entered into a settlement agreement (the “Settlement Agreement”) and an asset sale agreement (the “Asset Sale Agreement”), each dated as of the date hereof which, among other things, provide that TEMIC or its nominee are to be assigned certain intellectual property relating to the extraction of a product from bovine bile marketed in association with the trademark “Virulizin” as evidenced by the patents, trademarks and other intellectual property rights (including without limitation, the Patent Rights, as defined below) described in Schedule “A” hereto”;
ZOR PHARMACEUTICALS, LLC LIMITED LIABILITY COMPANY AGREEMENTLimited Liability Company Agreement • September 27th, 2012 • Lorus Therapeutics Inc • Biological products, (no disgnostic substances) • Delaware
This LIMITED LIABILITY COMPANY AGREEMENT is made by and between the Persons named on Schedule A (such Persons are referred to collectively as the “Members” and individually as a “Member”) on April 8, 2008.
ASSET PURCHASE AGREEMENT BETWEEN LORUS THERAPEUTICS INC. AND THE ERIN MILLS INVESTMENT CORPORATION MADE AS OF June 19, 2009Asset Purchase Agreement • September 27th, 2012 • Lorus Therapeutics Inc • Biological products, (no disgnostic substances) • Ontario
WHEREAS the Vendor and the Purchaser have entered into a settlement agreement (the "Settlement Agreement") as of the date hereof pursuant to which the Vendor has agreed to sell and the Purchaser will accept certain of the assets of the Vendor in partial settlement of the Debentures (as that term is defined in the Settlement Agreement), upon and subject to the terms and conditions set out in this Agreement;
SHARE PURCHASE AGREEMENT BETWEEN THE ERIN MILLS INVESTMENT CORPORATION AND LORUS THERAPEUTICS INC. MADE AS OF JUNE 19, 2009Share Purchase Agreement • September 27th, 2012 • Lorus Therapeutics Inc • Biological products, (no disgnostic substances) • Ontario
AND WHEREAS the Purchaser and the Vendor have entered into a settlement agreement (the "Settlement Agreement") dated the date hereof, pursuant to which the Vendor has agreed to sell and the Purchaser has agreed to purchase the Shares upon and subject to the terms and conditions hereinafter set forth;
AMENDMENT, ASSIGNMENT, ASSUMPTION, NOVATION AND CONSENT AGREEMENTAmendment, Assignment, Assumption, Novation and Consent Agreement • September 27th, 2012 • Lorus Therapeutics Inc • Biological products, (no disgnostic substances) • Ontario
WHEREAS on October 6, 2004, Lorus Therapeutics Inc. (formerly 4325231 Canada Inc.) (“Old Lorus”), GeneSense Technologies Inc. (“GeneSense”) and TEMIC entered into a subscription agreement providing for the issuance of three (3) five million dollar ($5,000,000) principal amount convertible debentures (each a “Debenture” and collectively, the “Debentures”) on each of October 6, 2004, January 14, 2005 and April 15, 2005, each maturing on October 6, 2009;
INDEPENDENT CONTRACTOR SERVICES AGREEMENTIndependent Contractor Services Agreement • September 27th, 2012 • Lorus Therapeutics Inc • Biological products, (no disgnostic substances) • Ontario
This agreement (the “Agreement”) is made by and between Zor Pharmaceuticals, LLC (the “Company”), located at 100-A Eastwood Center Dr., Suite 118 Wilmington, NC 28403 U.S.A., and Genesense Technologies Inc. located at 2 Meridian Road, Toronto, ON, Canada M9W 4Z7 (the “Contractor”).
